Lyell Immunopharma (LYEL) EBIT Margin Growth (3y) (2023 - 2026)

Lyell Immunopharma (LYEL) EBIT Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,942.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Lyell Immunopharma 298.14 Mn 298.14 Mn - -211.68 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -211.68 Mn
Dec 31, 2025 -212.74 Mn
Sep 30, 2025 196.62 Mn
Jun 30, 2025 -58.91 Mn
Mar 31, 2025 -80.71 Mn
Dec 31, 2024 -182.69 Mn
Sep 30, 2024 -14.68 Mn
Jun 30, 2024 -39.40 Mn
Mar 31, 2024 -185.02 Mn
Dec 31, 2023 -45.60 Mn
Sep 30, 2023 -23.27 Mn
Jun 30, 2023 -24.08 Mn